Quick Facts: Main Uses

• Addresses symptoms associated with: Osteoarthritis
• Manages symptoms of: Rheumatoid arthritis
• Helps relieve: Mild to moderate pain, including menstrual pain
• Contributes to relief in: Ankylosing spondylitis

What Dolomax (Ketoprofen) Treats: Main Uses and Benefits

Dolomax, which contains the active substance ketoprofen, is a therapeutic option used for the management of pain and inflammation in several conditions. Its principal approved applications center on its ability to help relieve symptoms associated with chronic joint conditions and various forms of acute pain.

The medication is indicated to provide relief for the signs and symptoms of rheumatoid arthritis and osteoarthritis, which are characterized by pain and stiffness in the joints. For these chronic conditions, ketoprofen can assist in improving functional status and general comfort. In addition, it is used for the management of ankylosing spondylitis.

Dolomax also serves as a supportive measure in acute settings. It is utilized to help relieve mild to moderate pain stemming from diverse causes, including pain following surgery, pain related to soft-tissue injuries such as sprains or strains, and menstrual pain (primary dysmenorrhea). The therapeutic application of ketoprofen is well-established in clinical practice for these areas.

Ketoprofen (Dolomax) eligibility is strictly defined by patient history, physiological state, and existing medical conditions, as specified in regulatory documents.

Populations that Must Not Use Ketoprofen (Contraindicated)

Populations with Restricted or Conditional Use

Interactions with other medicines and products

The official interaction profile for Dolomax (Ketoprofen) is defined by its potential to cause additive pharmacodynamic risk and to alter the systemic exposure of co-administered drugs.

Contraindicated and High-Risk Combinations

Co-administration of other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors and high-dose Aspirin, is formally contraindicated due to a significantly increased risk of serious gastrointestinal events, such as bleeding and ulceration, as stated in regulatory guidance. Interactions affecting hemorrhage risk are also documented for Anticoagulants (like Warfarin), Antiplatelet agents, Corticosteroids, and SSRIs; concomitant use with these categories increases the risk of bleeding.

Exposure and Elimination Interactions

Ketoprofen can alter the clearance of certain medicines. It is documented that ketoprofen elevates the plasma concentration of Lithium and reduces the clearance of Methotrexate, thereby increasing the potential for toxicity of both drugs. Furthermore, ketoprofen may diminish the antihypertensive effect of ACE Inhibitors and ARBs, and the diuretic effect of agents like Furosemide. Co-administration with these drugs may also be associated with an increased risk of acute renal function impairment.

Food and Population Notes

In elderly subjects or those with renal impairment, the clearance of ketoprofen's metabolite is reduced, which can lead to accumulation of the active drug. A high-fat meal has been shown to cause a delay in reaching the peak plasma concentration (C max) of the extended-release formulation.

Mechanism of Action: Dual COX and LOX Enzyme Inhibition

The primary mechanism involves the non-selective inhibition of the Cyclooxygenase (COX) enzymes ( COX-1 and COX-2), which prevents the synthesis of prostaglandins. Ketoprofen also demonstrates inhibitory action on the Lipooxygenase (LOX) pathway, which modulates the production of leukotrienes. This dual molecular blockade limits the synthesis of two distinct families of key inflammatory mediators, resulting in the modulation of the eicosanoid cascade through dual pathway interference.

Modulation of Pain Signaling and Thermoregulation

The reduction in pro-inflammatory prostaglandins alters two physiological systems: peripheral nociceptive signaling and central thermoregulation. The mechanism lowers mediator activity at the peripheral site of irritation, which reduces the sensitization of nerve endings and increases the required level of stimulus for nociceptor activation. Simultaneously, the suppression of PGE2 synthesis within the hypothalamus alters the elevated body temperature set-point toward basal levels.

Physiological Constraints on Mechanistic Scope

The effectiveness of this mechanism is directly proportional to the involvement of prostaglandin and leukotriene pathways in a given physiological state. The mechanism addresses the chemical mediators of inflammation but does not engage in processes of tissue repair or resolution of the underlying cause. The action is constrained where the physiological state is primarily mediated by pathways independent of the arachidonic acid cascade.

Ketoprofen administration is officially approved via oral and topical routes. The oral forms include both immediate-release (IR) and extended-release (ER) capsules or tablets. The standard adult regimen for chronic conditions using IR forms involves doses of 50 mg four times a day or 75 mg three times a day, with a maximum daily prescription dose of 300 mg. The ER formulation is taken once daily at a dose of 200 mg and is not recommended for acute pain.

When taking oral ketoprofen, it may be consumed with food, milk, or antacids and must be taken with a full glass of water. Extended-release capsules or tablets must be swallowed whole and must not be broken or chewed.

For acute, as-needed use, IR dosing is typically 25 mg to 50 mg every 6 to 8 hours. The overarching principle for all use is to employ the lowest effective dose for the shortest possible duration. Specific population adjustments apply, requiring the initiation of lower doses for older adults and individuals with kidney or liver impairment, with mandatory maximum daily dose ceilings.

When using the topical gel, it is applied 2 to 4 times daily, and the maximum duration of use is generally not to exceed 7 to 10 days. A key procedural condition for topical use is that the treated areas must be protected from direct sunlight or UV exposure during therapy and for two weeks after discontinuation.

Research evidence / Overview of studies for Dolomax (Ketoprofen)

Research for Chronic Joint Conditions (Osteoarthritis and Rheumatoid Arthritis)

The evidence base for ketoprofen in studies exploring symptomatic patterns associated with chronic conditions, such as osteoarthritis (OA) and rheumatoid arthritis (RA), is largely built on short-term Randomized Controlled Trials (RCTs) and subsequent reviews that combine data from multiple studies (meta-analyses). Researchers focused primarily on monitoring symptom evolution over time in adults with established conditions. Outcomes related to physical discomfort were the main focus, utilizing standard measures like validated pain scales and scores that reflect daily functioning or activity level. These studies generally monitored responses over defined time intervals, typically lasting up to three months.

Studies reported measurements of symptom intensity for both OA and RA. Findings describe group patterns related to how patient-reported discomfort evolved, including measures of pain and morning stiffness. Studies often used an active comparator or placebo, meaning research explored measured endpoints relative to other agents studied concurrently. According to regulatory reviews, the available studies provide limited information regarding long-term measured endpoints, particularly concerning the stability of observed functional changes or how symptoms change after the initial study period has ended.

Evidence for Acute and Short-Term Pain Relief

For conditions characterized by acute or disruptive episodes, such as pain following a surgical procedure or primary menstrual pain (dysmenorrhea), research examined ketoprofen using different study designs. For surgical pain models, studies often involved a single administration to track rapid symptom evolution, making them very short-term. For conditions like dysmenorrhea, research explored short-term symptom changes over the course of a single episode. The outcomes monitored were related to acute changes, specifically focusing on the speed of relief and the duration of its observed pattern.

Research exploring short-term symptom changes reported how symptoms evolved in the observed populations within a few hours of administration. Studies focusing on episodes where symptoms become more noticeable documented patterns related to the intensity of symptomatic change documented. For acute pain scenarios, studies monitored patterns related to the frequency of rescue medication use—that is, additional pain relievers. The evidence base is heavily concentrated on single-dose efficacy models, which means results apply only to the populations studied under those specific, short-term research scenarios.

Research Gaps and Uncertainties

The evidence landscape highlights several areas where the research remains incomplete. One key research limitation is that follow-up durations were limited in many of the core efficacy trials, meaning long-term measured endpoints are not well characterized. Furthermore, comparative evidence is lacking in some areas, specifically when assessing ketoprofen against newer treatments or when comparing different formulations (oral versus injectable versus topical) across a wide range of conditions. Subgroup findings are uncertain, especially for patients with specific, pre-existing health issues, as results apply only to the populations studied in the original clinical trials.

Key Studies & References Ketoprofen - LiverTox - NCBI Bookshelf - NIH (General Overview and Indications)

Common questions about Dolomax (Ketoprofen) (FAQ)

Q: What is the proper way to store Drug X?

Official drug information states that Dolomax (Ketoprofen) should be stored at controlled room temperature, which is generally between 20 C to 25 C (68 F to 77 F). The packaging allows for brief temperature excursions between 15 C to 30 C (59 F to 86 F). Regulatory guidelines emphasize keeping the medication out of reach of children.

Q: Will Drug X make me feel drowsy or affect my ability to drive?

The official product labeling indicates that dizziness and somnolence (drowsiness) are reported as potential side effects. Due to these potential effects on the central nervous system, official labeling suggests patients should be aware of how the drug affects them prior to activities requiring alertness, such as driving or operating heavy machinery.

Q: Is it safe to drink alcohol while taking Drug X?

Regulatory warnings suggest avoiding or limiting alcohol consumption while using Dolomax (Ketoprofen). Combining alcohol with this medication may increase the risk of experiencing specific adverse reactions, such as increased dizziness or drowsiness.

Q: How should Drug X be taken—with or without food?

Regulatory information from official labels states that Dolomax (Ketoprofen) can be taken with or without food. For consistent use, product information indicates that maintaining a consistent routine (always with food or always without) may be preferable.

Q: Who should not take Drug X?

The official contraindications section lists specific individuals who should not take Dolomax (Ketoprofen). This medication is contraindicated if a patient has a known hypersensitivity (severe allergic reaction) to the drug's components or if they have a history of severe liver impairment.

Q: What happens if I miss a dose of Drug X?

If a dose of Dolomax (Ketoprofen) is missed, official patient information suggests taking the dose as soon as it is remembered. However, if the time is close to when the next scheduled dose is due, the recommended action is to skip the missed dose entirely and continue with the regular schedule. Official guidelines caution against taking two doses at the same time.

Storage and Disposal Requirements for Ketoprofen

Ketoprofen capsules must be stored at Controlled Room Temperature, defined as 20 to 25 C (68 to 77 F), to maintain product stability. The medication requires protection from light and excessive moisture and must be kept in a tightly closed, light-resistant container. For safety, it must be stored out of the sight and reach of children and not in high-humidity areas, such as the bathroom.

For disposal, unused or expired Ketoprofen should be taken to an official drug take-back program. If one is unavailable, the drug should be mixed with an undesirable substance (e.g., cat litter) and sealed in a bag for disposal in the household trash. The medication must not be disposed of via wastewater (flushed down the toilet or sink).